• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Synergy CHC Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    12/6/24 8:31:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care
    Get the next $SNYR alert in real time by email
    false 0001562733 0001562733 2024-12-06 2024-12-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): December 6, 2024

     

    SYNERGY CHC CORP.

    (Exact name of registrant as specified in its charter)

     

    Nevada   000-55098   99-0379440
    (State or Other Jurisdiction   (Commission File Number)   (IRS Employer
    of Incorporation)     Identification No.)

     

    865 Spring Street, Westbrook, Maine   04092
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (902) 237-1220

     

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock   SNYR   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 2.02. Results of Operations and Financial Condition.

     

    On December 6, 2024, Synergy CHC Corp. (the “Company”) issued a press release announcing its financial and operating results for the quarter ended September 30, 2024. A copy of the press release is furnished herewith as Exhibit 99.1.

     

    The information in Item 2.02 of this Current Report on Form 8-K and the press release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

     

    Item 7.01 Regulation FD Disclosure.‌

     

    On December 6, 2024, the Company issued the press release described above in Item 2.02 of this Current Report on Form 8-K. The press release is attached as Exhibit 99.1 and incorporated into this Item 7.01 by reference.

     

    All statements in the press release, other than historical financial information, may be deemed to be forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results or developments may differ materially from those in the forward-looking statements. See the Company’s other filings with the Securities and Exchange Commission (the “SEC”) for a discussion of other risks and uncertainties. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

     

    The information in this Current Report on Form 8-K under Item 7.01 is being “furnished” and not “filed” with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under such section. Furthermore, such information shall not be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, unless specifically identified as being incorporated therein by reference. 

     

    Item 9.01 Financial Statements and Exhibits.‌

     

    (d) Exhibits

     

    Exhibit No.

      Description
    99.1   Press Release, dated December 6, 2024
    104   Cover Page Interactive Data File (embedded within the inline XBRL document)

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: December 6, 2024  
       
      SYNERGY CHC CORP.
         
      By: /s/ Jack Ross
      Name:  Jack Ross
      Title: Chief Executive Officer

     

     

    2

     

    Get the next $SNYR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNYR

    DatePrice TargetRatingAnalyst
    1/21/2025$10.00Buy
    ROTH MKM
    More analyst ratings

    $SNYR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and Chairman Ross Jack bought $10,870 worth of shares (5,300 units at $2.05), increasing direct ownership by 1% to 366,507 units (SEC Form 4)

      4 - Synergy CHC Corp. (0001562733) (Issuer)

      5/21/25 5:05:31 PM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • CEO and Chairman Ross Jack bought $39,350 worth of shares (14,340 units at $2.74), increasing direct ownership by 4% to 361,207 units (SEC Form 4)

      4 - Synergy CHC Corp. (0001562733) (Issuer)

      5/21/25 4:46:18 PM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • CEO and Chairman Ross Jack bought $59,521 worth of shares (15,200 units at $3.92), increasing direct ownership by 5% to 346,877 units (SEC Form 4)

      4 - Synergy CHC Corp. (0001562733) (Issuer)

      3/3/25 9:25:39 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care

    $SNYR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Synergy CHC Announces New $20 Million Long-Term Credit Facility

      WESTBROOK, Maine, June 04, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a provider of consumer health care and lifestyle products, announced today that it has entered into a $20 million term loan credit agreement, due May 2029 with ACP Agency, LLC. The proceeds will be used to pay down debt and provide the Company with growth capital. Under the terms of the agreement, the Company received a $15 million term loan at closing, with an interest rate of SOFR plus 8.5%. The loan is interest-only through 2025, with quarterly principal payments of $175,000 beginning in January 2026, increasing to $350,000 per quarter in 2027 and beyond. A $2.5 million de

      6/4/25 8:30:00 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • Synergy CHC Announces Appointment of Erik Shields as Vice President of Beverage

      WESTBROOK, Maine, May 29, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a provider of consumer health care and lifestyle products, announced today that Erik Shields has been named Vice President of Beverage of Synergy, effective May 26, 2025. "We're excited to welcome Erik to the team and look forward to his contributions," said Jack Ross, CEO of Synergy. "With nearly two decades of experience leading national strategies, managing key accounts, and building high-performance teams, Erik brings the leadership and executional expertise needed to help scale our beverage business. As we focus on accelerating growth in this category, we're confident he w

      5/29/25 8:00:00 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • Synergy CHC Corp Reports Growth in Earnings Per Share for its First Quarter 2025 Financial Results and its Ninth Consecutive Quarter of Profitability

      WESTBROOK, Maine, May 15, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a provider of consumer health care and lifestyle products, is announcing its financial results for the three months ended March 31, 2025. "We are very pleased to report 30% growth in earnings per share year-over-year, marking our ninth consecutive quarter of profitability," said Jack Ross, CEO of Synergy. "Additionally, we expanded our EBITDA margins significantly to 24.1% compared to 19.7% in the prior year period. This performance highlights the strength of our operating model and our ongoing discipline around cost management." "We continue to make meaningful progress toward

      5/15/25 8:00:00 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care

    $SNYR
    Financials

    Live finance-specific insights

    See more
    • Synergy CHC Corp Reports Growth in Earnings Per Share for its First Quarter 2025 Financial Results and its Ninth Consecutive Quarter of Profitability

      WESTBROOK, Maine, May 15, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a provider of consumer health care and lifestyle products, is announcing its financial results for the three months ended March 31, 2025. "We are very pleased to report 30% growth in earnings per share year-over-year, marking our ninth consecutive quarter of profitability," said Jack Ross, CEO of Synergy. "Additionally, we expanded our EBITDA margins significantly to 24.1% compared to 19.7% in the prior year period. This performance highlights the strength of our operating model and our ongoing discipline around cost management." "We continue to make meaningful progress toward

      5/15/25 8:00:00 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • Synergy CHC Corp. Announces First Quarter 2025 Earnings and Conference Call Information

      WESTBROOK, Maine, May 01, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a provider of consumer health care and lifestyle products, announced today that it plans to release financial results for the first quarter ended March 31, 2025, on Thursday, May 15, 2025, before the open of market trading. In conjunction with reporting first quarter 2025 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Synergy's website. To access the call by

      5/1/25 4:05:00 PM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • Synergy CHC Corp. Announces Fourth Quarter and Full Year 2024 Earnings and Conference Call Information

      WESTBROOK, Maine, March 20, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a provider of consumer health care and lifestyle products, announced today that it plans to release financial results for the fourth quarter and full year ended December 31, 2024, on Monday, March 31, 2025, before the open of market trading. In conjunction with reporting fourth quarter and full year 2024 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Syner

      3/20/25 4:05:00 PM ET
      $SNYR
      Other Pharmaceuticals
      Health Care

    $SNYR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and Chairman Ross Jack bought $10,870 worth of shares (5,300 units at $2.05), increasing direct ownership by 1% to 366,507 units (SEC Form 4)

      4 - Synergy CHC Corp. (0001562733) (Issuer)

      5/21/25 5:05:31 PM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • CEO and Chairman Ross Jack bought $39,350 worth of shares (14,340 units at $2.74), increasing direct ownership by 4% to 361,207 units (SEC Form 4)

      4 - Synergy CHC Corp. (0001562733) (Issuer)

      5/21/25 4:46:18 PM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • CEO and Chairman Ross Jack bought $59,521 worth of shares (15,200 units at $3.92), increasing direct ownership by 5% to 346,877 units (SEC Form 4)

      4 - Synergy CHC Corp. (0001562733) (Issuer)

      3/3/25 9:25:39 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care

    $SNYR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $SNYR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $SNYR
    SEC Filings

    See more
    • SEC Form SC 13D filed by Synergy CHC Corp.

      SC 13D - Synergy CHC Corp. (0001562733) (Subject)

      10/31/24 9:55:58 PM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Synergy CHC Corp.

      SC 13G - Synergy CHC Corp. (0001562733) (Subject)

      10/25/24 7:46:44 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • ROTH MKM initiated coverage on Synergy CHC Corp. with a new price target

      ROTH MKM initiated coverage of Synergy CHC Corp. with a rating of Buy and set a new price target of $10.00

      1/21/25 9:10:17 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • Synergy CHC Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

      8-K - Synergy CHC Corp. (0001562733) (Filer)

      6/4/25 8:37:50 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • SEC Form 10-Q filed by Synergy CHC Corp.

      10-Q - Synergy CHC Corp. (0001562733) (Filer)

      5/15/25 8:05:55 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • Synergy CHC Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Synergy CHC Corp. (0001562733) (Filer)

      5/15/25 8:00:17 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care

    $SNYR
    Leadership Updates

    Live Leadership Updates

    See more
    • Synergy CHC Announces Appointment of Erik Shields as Vice President of Beverage

      WESTBROOK, Maine, May 29, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a provider of consumer health care and lifestyle products, announced today that Erik Shields has been named Vice President of Beverage of Synergy, effective May 26, 2025. "We're excited to welcome Erik to the team and look forward to his contributions," said Jack Ross, CEO of Synergy. "With nearly two decades of experience leading national strategies, managing key accounts, and building high-performance teams, Erik brings the leadership and executional expertise needed to help scale our beverage business. As we focus on accelerating growth in this category, we're confident he w

      5/29/25 8:00:00 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care